Sukhwinder Sohal

Dr. Sukhwinder Sohal

Respiratory Translational Research Group, Department of Laboratory Medicine, College of Health and Medicine, University of Tasmania, Launceston, TAS 7248, Australia

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 March 2020 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
SBSamuel James Brake
Samuel James Brake
KBKathryn Barnsley
Kathryn Barnsley
WLWenying Lu
Wenying Lu
KMKielan McAlinden
Kielan McAlinden
MEMathew Suji Eapen
Mathew Suji Eapen
Sukhwinder SohalSukhwinder Sohal
Sukhwinder Sohal
The epicenter of the original outbreak in China has high male smoking rates of around 50%, and early reported death rates have an emphasis on older males, therefore the likelihood of smokers being overrepresented in fatalities is high. In Iran, China, Italy, and South Korea, female smoking rates are much lower than males. Fewer females have contracted the virus. If this analysis is correct, then Indonesia would be expected to begin experiencing high rates of Covid-19 because its male smoking rate is over 60% (Tobacco Atlas). Smokers are vulnerable to respiratory viruses. Smoking can upregulate angiotensin-converting enzyme-2 (ACE2) receptor, the known receptor for both the severe acute respiratory syndrome (SARS)-coronavirus (SARS-CoV) and the human respiratory coronavirus NL638. This could also be true for new electronic smoking devices such as electronic cigarettes and “heat-not-burn” IQOS devices. ACE2 could be a novel adhesion molecule for SARS-CoV-2 causing Covid-19 and a potential therapeutic target for the prevention of fatal microbial infections, and therefore it should be fast tracked and prioritized for research and investigation. Data on smoking status should be collected on all identified cases of Covid-19.

21 July 2017 in Developmental Dynamics
Verified
Journal Article
Closed access
PDF file
MJMohit Kumar Jolly
Mohit Kumar Jolly
CWChronic Ward
Chronic Ward
MEMathew Suji Eapen
Mathew Suji Eapen
SMStephen Myers
Stephen Myers
OHOskar Hallgren
Oskar Hallgren
Sukhwinder SohalSukhwinder Sohal
Sukhwinder Sohal

17 October 2017 in Scientific Reports
Verified
Journal Article
Open access
PDF file
MEMathew Suji Eapen
Mathew Suji Eapen
PHPhilip M. Hansbro
Philip M. Hansbro
KMKielan McAlinden
Kielan McAlinden
RKRichard Y. Kim
Richard Y. Kim
CWChronic Ward
Chronic Ward
Sukhwinder SohalSukhwinder Sohal
Sukhwinder Sohal
We explore potential dysregulation of macrophage phenotypes in COPD pathogenesis through integrated study of human small airway tissue, bronchoalveolar lavage (BAL) and an experimental murine model of COPD. We evaluated human airway tissue and BAL from healthy controls, normal lung function smokers (NLFS), and COPD subjects. Both small airways and BAL cells were immunohistochemically stained with anti-CD68 for total macrophages and with anti-CD163 for M2, and anti-iNOS for M1 macrophages. Multiplex ELISA measured BAL cytokines. Comparable cigarette smoke-induced experimental COPD mouse model was assessed for relevant mRNA profiles. We found an increase in pro-inflammatory M1s in the small airways of NLFS and COPD compared to controls with a reciprocal decrease in M2 macrophages, which remained unchanged among pathological groups. However, luminal macrophages showed a dominant M2 phenotype in both NLFS and COPD subjects. BAL cytokine skewed towards an M2 profile with increase in CCL22, IL-4, IL-13, and IL-10 in both NLFS and COPDs. The mouse-model of COPD showed similar increase in mRNA for M2 markers. Our finding suggests abnormal macrophage switching in both mucosal and luminal areas of COPD patients, that strongly associated with cytokine balance. There may be potential for beneficial therapeutic cytokine manipulation of macrophage phenotypes in COPD.

21 July 2010 in Respirology
Verified
Journal Article
Closed access
PDF file
Sukhwinder SohalSukhwinder Sohal
Sukhwinder Sohal
DRDavid Reid
David Reid
ASAmir Soltani
Amir Soltani
CWChronic Ward
Chronic Ward
SWSteven Weston
Steven Weston
HWHaydn Walters
Haydn Walters

1 September 2021 in The Lancet Respiratory Medicine
Verified
Journal Article
Closed access
PAPurva Asrani
Purva Asrani
MEMathew Suji Eapen
Mathew Suji Eapen
IHImtaiyaz Hassan
Imtaiyaz Hassan
Sukhwinder SohalSukhwinder Sohal
Sukhwinder Sohal

2 August 2017 in Expert Review of Respiratory Medicine
Verified
Journal Article
Closed access
MEMathew Suji Eapen
Mathew Suji Eapen
SMStephen Myers
Stephen Myers
EWEugene Haydn Walters
Eugene Haydn Walters
Sukhwinder SohalSukhwinder Sohal
Sukhwinder Sohal
Introduction: Chronic obstructive pulmonary disease (COPD) is primarily an airway condition, which mainly affects cigarette smokers and presents with shortness of breath that is progressive and poorly reversible. In COPD research, there has been a long held belief that airway disease progression is due to inflammation. Although this may be true in the airway lumen with innate immunity activated by the effect of smoke or secondary to infection, the accurate picture of inflammatory cells in the airway wall, where the pathophysiological COPD remodeling occurs, is uncertain and debatable. Areas covered: The current review provides a comprehensive literature survey of the changes in the main inflammatory cells in human COPD patients and focuses on contrarian views that affect the prevailing dogma on inflammation. The review also delves into the role of oxidative stress and inflammasomes in modulating the immune response in COPD. Further, the effects of inflammation in affecting the epithelium, fibroblasts, and airway remodeling are discussed. Expert commentary: Inflammation as a driving force for airway wall damage and remodelling in early COPD is at the very least ‘oversimplified’ and is likely to be misleading. This has serious implications for rational thinking about the illness, including pathogenesis and designing therapy.